Acetaminophen Micronized

證據等級: L5

預測適應症: 0 個

Acetaminophen Micronized: Insufficient Data for Repurposing Prediction

One-Sentence Summary

Acetaminophen Micronized is a particle-size-reduced formulation of the well-known analgesic and antipyretic acetaminophen (paracetamol), commonly used for mild-to-moderate pain relief and fever reduction. The TxGNN model returned no predicted new indications for this compound, likely due to the absence of a matched DrugBank ID for the micronized formulation variant. Without a TxGNN score or supporting evidence, a formal repurposing evaluation cannot proceed at this stage.

Quick Overview

Item	Content
Original Indication	Analgesic / Antipyretic (general pharmaceutical knowledge; no TFDA registration data available)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — not applicable; no prediction generated)
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for this entry. The pipeline query log shows that a DrugBank lookup was attempted and returned one result (result_count: 1), but no drugbank_id was successfully mapped into the candidate record. Without a valid DrugBank identifier, TxGNN cannot traverse the knowledge graph to generate disease associations.

Acetaminophen (INN: paracetamol) is one of the most widely used over-the-counter analgesics globally, with a well-characterised mechanism involving cyclooxygenase inhibition in the central nervous system and modulation of the endocannabinoid system. The "micronized" designation refers to a pharmaceutical particle-size reduction process intended to improve dissolution rate and bioavailability — it is the same active moiety, not a distinct chemical entity.

To unlock TxGNN predictions, the canonical DrugBank entry for acetaminophen (DB00316) should be explicitly linked to this candidate before re-running the prediction pipeline.

Singapore Market Information

This drug is currently not registered in Singapore under the Health Sciences Authority (HSA). No license records are available.

Safety Considerations

Please refer to the package insert for safety information. No DDI records, contraindications, or key warnings were retrieved during the current data collection cycle.

Note for reviewers: The TFDA package insert (仿單) was flagged as a blocking data gap (DG001). Until this document is retrieved and parsed, a formal safety profile cannot be constructed.

Conclusion and Next Steps

Decision: Hold

Rationale: The absence of TxGNN predictions, a missing DrugBank ID linkage, and zero Singapore regulatory registrations mean there is no actionable repurposing signal to evaluate at this time. The underlying active ingredient (acetaminophen) is well-characterised, but this specific formulation variant has not been processed through the full pipeline.

To proceed, the following is needed:

Resolve DrugBank ID mapping — Explicitly assign DrugBank ID DB00316 (acetaminophen) to this candidate and re-run the TxGNN prediction pipeline (scripts/run_kg_prediction.py)
Retrieve TFDA package insert — Download and parse the TFDA 仿單 PDF to populate key warnings, contraindications, and MOA fields (Data Gap DG001, severity: Blocking)
Confirm formulation intent — Clarify whether "micronized" is being evaluated as a standalone entity or as a formulation variant of standard acetaminophen; this determines whether a separate evidence collection run is warranted
Re-run evidence collection — After DrugBank ID is resolved, re-run ClinicalTrials.gov and PubMed collectors to populate the evidence pack
HSA registration check — Verify whether any acetaminophen micronized products are under pending HSA registration or are covered under existing acetaminophen monograph approvals in Singapore
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.